| Not Yet Recruiting | Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma Extranodal NK/T-cell Lymphoma | Phase 3 | 2026-06-01 |
| Recruiting | A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 / Phase 2 | 2025-02-24 |
| Completed | Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real Gastrointestinal Stromal Tumors | — | 2022-08-29 |
| Active Not Recruiting | A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer | Phase 2 | 2022-05-27 |
| Recruiting | A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas Advanced Solid Tumor, Advanced Lymphoma | Phase 1 | 2022-03-28 |
| Completed | Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients Relapsed Small Cell Lung Cancer | Phase 1 | 2021-01-12 |
| Completed | A Study of CS3005 in Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2020-01-10 |
| Terminated | A Study of CS3002 in Subjects With Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2019-12-30 |
| Completed | A Phase I Study of CS1002 in Subjects With Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2019-12-27 |
| Completed | A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | Phase 3 | 2019-12-19 |
| Completed | A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma Hepatocellular Carcinoma | Phase 1 / Phase 2 | 2019-12-16 |
| Active Not Recruiting | A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma Hepatocellular Carcinoma | Phase 3 | 2019-12-13 |
| Completed | A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors Advanced Refractory Solid Tumors | Phase 1 / Phase 2 | 2019-12-13 |
| Completed | A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | 2019-11-12 |
| Completed | A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor Gastrointestinal Stromal Tumors | Phase 1 / Phase 2 | 2019-08-15 |
| Completed | A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 3 | 2019-03-28 |
| Active Not Recruiting | A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer Non Small Cell Lung Cancer | Phase 3 | 2018-12-13 |
| Completed | A Study of CS1001 in Subjects with Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2018-12-04 |
| Completed | A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas Solid Tumor, Lymphoma | Phase 1 | 2018-10-29 |
| Completed | A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer Stage III | Phase 3 | 2018-10-26 |
| Completed | Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors Locally Advanced or Metastatic Solid Tumors | Phase 1 | 2018-10-19 |
| Completed | A Study of CS3006 in Subjects with Locally Advanced or Metastatic Solid Tumors Solid Tumor, Adult | Phase 1 | 2018-06-14 |
| Completed | A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL) Extranodal Natural Killer/T-Cell Lymphoma | Phase 2 | 2018-06-12 |
| Completed | A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma Hodgkin Lymphoma | Phase 2 | 2018-05-22 |
| Completed | A Study of CS1003 in Subjects With Advanced Solid Tumors Advanced Cancer | Phase 1 | 2018-05-09 |
| Completed | A Study of CS1002 in Subjects with Advanced Solid Tumors Solid Tumor, Adult | Phase 1 | 2018-04-26 |
| Completed | A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors Advanced Cancer | Phase 1 | 2017-10-19 |